TAIC FOLFOX for unresectable gastric and gastroesophageal junction cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial treats adults with pathologically confirmed unresectable gastric cancer or gastroesophageal junction adenocarcinoma. Participants receive transarterial infusion chemotherapy (TAIC) combined with standard FOLFOX (5-FU, leucovorin, oxaliplatin) to target tumors while potentially reducing systemic exposure. Eligibility includes confirmed unresectable disease, frailty or comorbidities precluding surgery, and an expected survival of at least 3 months, with several medical exclusions. The study is sponsored by Guang'anmen Hospital and conducted in Beijing, China. Outcomes will inform whether this targeted chemotherapeutic approach can improve survival and quality of life for this patient group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Pathologically diagnosed with G/GEJA
* Confirmed by the surgeon as initially unresectable advanced G/GEJC
* Contraindicated to surgery due to frailty or comorbidities
* Expected survival period ≥ 3 months

Exclusion Criteria:

* Primary malignant tumors
* Gastrointestinal obstruction caused by lesions in the distal stomach, duodenum, pancreas or other organs
* Acute infection, severe liver or kidney dysfunction or coagulation disorder
* Allergic to the drugs or with mental disorders

Where it's running

• Department of General Surgery, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange St, West-city District, Beijing, China
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yan Sun, PhD
• Email: 632739616@qq.com
• Phone: +86 15010797262

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer

  Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.

  Recruiting Hebei Medical University · Shijiazhuang, None Selected · NCT07849608

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• Chemoradiotherapy with CAPOX and SHR-1701 for unresectable gastric or GEJ cancer

  This study tests whether adding SHR-1701 to radiotherapy and CAPOX helps patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer see if they harm or help, with the goal of delaying progression and enabling possible surgery.

  Recruiting at 3 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Shenzhen, Guangdong and 2 other locations · NCT07689851

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.